Simonsson B, Danersund A, Tötterman T H, Nilsson K, Wibell L
Scand J Haematol. 1986 May;36(5):424-9. doi: 10.1111/j.1600-0609.1986.tb02276.x.
The in vitro production of beta 2-microglobulin (beta 2m) by leukaemic cells was studied in 22 patients with chronic B-lymphocytic leukaemia (CLL). In addition, the concentration of beta 2m in serum (S-beta 2m) was determined and expressed as percent of the upper normal limit, after a correction for elevated S-Creatinine values. Patients with progressive disease usually had CLL cells with a high rate of in vitro synthesis and an increased S-beta 2m. This was not found in patients with non-progressive disease. The in vitro synthesis of beta 2m X the lymphocyte count correlated with S-beta 2m in the total material (r = 0.65). The increased S-beta 2m frequently observed in CLL may therefore originate from the tumour cells. Hence, S-beta 2m is promising as a clinically useful tumour cell-associated marker in CLL.
对22例慢性B淋巴细胞白血病（CLL）患者的白血病细胞体外产生β2微球蛋白（β2m）的情况进行了研究。此外，测定血清中β2m的浓度（S-β2m），并在对升高的S-肌酐值进行校正后，以正常上限的百分比表示。病情进展的患者通常其CLL细胞体外合成率高且S-β2m升高。非进展性疾病患者未发现这种情况。β2m体外合成量×淋巴细胞计数与全部样本中的S-β2m相关（r = 0.65）。因此，CLL中经常观察到的S-β2m升高可能源于肿瘤细胞。因此，S-β2m有望成为CLL中具有临床实用价值的肿瘤细胞相关标志物。
